Patents Assigned to Research Corporation Technologies, Inc.
  • Patent number: 6861245
    Abstract: A method is provided for screening Caulobacter suitable for use as host organisms for secretion of heterologous polypeptides. Such Caulobacter have a transport protein homologous to one of the type I transport proteins known in C. crescentus. DNA constructs are also provided which code for a chimeric protein of which the C-terminus is a secretion signal of a Caulobacter surface layer protein, other than from C. crescentus. Bacterial cells containing, or which express such DNA constructs and which may secrete the resulting protein, are also provided.
    Type: Grant
    Filed: February 21, 2000
    Date of Patent: March 1, 2005
    Assignee: Research Corporation Technologies, Inc.
    Inventor: John Smit
  • Publication number: 20050033180
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from one of the higher order component signals of the received distorted signal.
    Type: Application
    Filed: August 18, 2004
    Publication date: February 10, 2005
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Ted Christopher
  • Publication number: 20040249280
    Abstract: A method and system for imaging a sample. The method includes the steps of generating an ultrasonic signal, directing the signal into a sample, which signal is distorted and contains a first order and higher order component signals at first and higher frequencies respectively. The received distorted signal is processed, and an image is formed, and then displayed, from one of the higher order component signals of the received distorted signal.
    Type: Application
    Filed: March 23, 2004
    Publication date: December 9, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Ted Christopher
  • Publication number: 20040247585
    Abstract: Fabry disease results from an X-linked deficiency in the enzyme &agr;-galactosidase A. The present invention is directed to recombinant human &agr;-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of &agr;-galactosidase A are also provided.
    Type: Application
    Filed: September 4, 2002
    Publication date: December 9, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventors: David Hudgins Calhoun, George Coppola
  • Patent number: 6825347
    Abstract: The present invention is directed to salts of the formula: or N-oxides thereof, and their use in preparing an amide.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: November 30, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Louis A. Carpino, Hideko Imazumi, Ayman El-Faham
  • Publication number: 20040220399
    Abstract: 1
    Type: Application
    Filed: May 27, 2004
    Publication date: November 4, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, Akireddy Srinivasa Rao, Venkata Ramana Doppalapudi
  • Patent number: 6770759
    Abstract: Compound of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting &bgr;-lactamase enzymes, for enhancing the activity of &bgr;-lactam antibiotics, and for treating &bgr;-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing compounds of formula I, and novel intermediates useful for the synthesis of compounds of formula I.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: August 3, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: John D. Buynak, Akireddy Srinivasa Rao, Venkata Ramana Doppalapudi
  • Publication number: 20040097416
    Abstract: The present invention is directed to the use of compounds of the formula: 1
    Type: Application
    Filed: October 17, 2003
    Publication date: May 20, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Publication number: 20040087508
    Abstract: The present invention is directed to the use of compounds of the formula: 1
    Type: Application
    Filed: October 17, 2003
    Publication date: May 6, 2004
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Robert H. Harris
  • Patent number: 6730499
    Abstract: The present invention provides formaldehyde dehydrogenase genes (FLD) from methylotrophic yeasts. The FLD structural genes confer resistance to formaldehyde and are therefore useful as a selectable marker in methylotrophic yeasts. The FLD promoter sequences are strongly and independently induced by either methanol as sole carbon source (with ammonium sulfate as nitrogen source) or methylamine as sole nitrogen source (with glucose as carbon source). Induction under either methanol, methylamine or both provides levels of heterologous gene expression comparable to those obtained with the commonly used alcohol oxidase I gene promoter (PAOX1). The FLD promoter of Pichia pastoris (PFLD1)is an attractive alternative to PAOX1 for expression of foreign genes in P. pastoris, allowing regulation by carbon (methanol) or nitrogen (methylamine) source within the same expression strain.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: May 4, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventor: James M. Cregg
  • Patent number: 6723697
    Abstract: In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: April 20, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 6713045
    Abstract: The invention relates to novel targeted magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
    Type: Grant
    Filed: November 16, 2000
    Date of Patent: March 30, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Thomas Meade, Scott Fraser, Russell Jacobs
  • Patent number: 6703199
    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: March 9, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 6699466
    Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16-mediated disorders such as certain inflammatory diseases.
    Type: Grant
    Filed: August 5, 1999
    Date of Patent: March 2, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
  • Patent number: 6673333
    Abstract: The invention relates to novel magnetic resonance imaging contrast agents for imaging cancer.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: January 6, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Thomas J. Meade, Scott Fraser, Russell Jacobs
  • Patent number: 6673901
    Abstract: A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding said monobody, and a variegated nucleic acid library encoding said monobody, are provided by the invention. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform said methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat/kuncat is greater than 10.
    Type: Grant
    Filed: June 12, 1998
    Date of Patent: January 6, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Patent number: 6670193
    Abstract: The present invention provides fluorescent nucleoside analogs which comprise a fluorescent cyclic compound joined to a carbon of a sugar molecule such as pentose, hexose, ribose or deoxyribose or analogs thereof in either an &agr; or &bgr; configuration. The subject compounds are useful as probes in the study of the structure and dynamics of nucleic acids and their complexes with proteins. In addition, the subject compounds are useful in any technique which uses labeled oligonucleotides for detection. Non-fluorescent spacer molecules in which a cyclohexane, cyclohexene, decalin, or benzene is joined to a carbon of a sugar moiety such as pentose, hexose, ribose or deoxyribose are also provided. Also provided are the 5′ dimethoxytrityl-3′-O-phosphoramidite derivatives, suitable for incorporation into oligonucleotides by automated synthesizers.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: December 30, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Eric T. Kool
  • Patent number: 6645725
    Abstract: The present invention provides a method for detecting endometriosis in a patient and is an improvement over invasive and expensive surgical procedures. The method employs immunoassays which detect autoantibodies in a serum sample which react with Thomsen-Friedenreich antigen (Tf). Increased levels of autoantibodies in a serum sample from the patient which bind to Tf-like antigen is indicative of endometriosis in the patient.
    Type: Grant
    Filed: April 19, 2001
    Date of Patent: November 11, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Grant R. Yeaman
  • Patent number: 6638504
    Abstract: The present invention is directed towards the diagnosis of malignant cancer by detection of the mts-1 MRNA or the mts-1 protein, encoded by the mts-1 gene. The present invention contemplates the use of recombinant mts-1 DNA and antibodies directed against the mts-1 protein to diagnose the metastatic potential of several types of tumor cells, including, for example, thyroid, epithelial, lung, liver and kidney tumor cells. The present invention is also directed to mammalian cell lines and tumors with high and low metastatic potential which have been developed to serve as tseful model systems for in vitro and in vivo anti-metastasis drug screening.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: October 28, 2003
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Eugene Lukanidin
  • Patent number: RE38551
    Abstract: The present invention is directed to a compound in the R configuration about the asymmetric carbon in the following formula: pharmaceutical compositions containing same and the use thereof in treating CNS disorders in animals.
    Type: Grant
    Filed: January 28, 2002
    Date of Patent: July 6, 2004
    Assignee: Research Corporation Technologies, Inc.
    Inventor: Harold Kohn